Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Lancet Digit Health ; 3(6): e360-e370, 2021 06.
Artigo em Inglês | MEDLINE | ID: mdl-34045002

RESUMO

BACKGROUND: Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis, which are typically transmitted via respiratory droplets, are leading causes of invasive diseases, including bacteraemic pneumonia and meningitis, and of secondary infections subsequent to post-viral respiratory disease. The aim of this study was to investigate the incidence of invasive disease due to these pathogens during the early months of the COVID-19 pandemic. METHODS: In this prospective analysis of surveillance data, laboratories in 26 countries and territories across six continents submitted data on cases of invasive disease due to S pneumoniae, H influenzae, and N meningitidis from Jan 1, 2018, to May, 31, 2020, as part of the Invasive Respiratory Infection Surveillance (IRIS) Initiative. Numbers of weekly cases in 2020 were compared with corresponding data for 2018 and 2019. Data for invasive disease due to Streptococcus agalactiae, a non-respiratory pathogen, were collected from nine laboratories for comparison. The stringency of COVID-19 containment measures was quantified using the Oxford COVID-19 Government Response Tracker. Changes in population movements were assessed using Google COVID-19 Community Mobility Reports. Interrupted time-series modelling quantified changes in the incidence of invasive disease due to S pneumoniae, H influenzae, and N meningitidis in 2020 relative to when containment measures were imposed. FINDINGS: 27 laboratories from 26 countries and territories submitted data to the IRIS Initiative for S pneumoniae (62 837 total cases), 24 laboratories from 24 countries submitted data for H influenzae (7796 total cases), and 21 laboratories from 21 countries submitted data for N meningitidis (5877 total cases). All countries and territories had experienced a significant and sustained reduction in invasive diseases due to S pneumoniae, H influenzae, and N meningitidis in early 2020 (Jan 1 to May 31, 2020), coinciding with the introduction of COVID-19 containment measures in each country. By contrast, no significant changes in the incidence of invasive S agalactiae infections were observed. Similar trends were observed across most countries and territories despite differing stringency in COVID-19 control policies. The incidence of reported S pneumoniae infections decreased by 68% at 4 weeks (incidence rate ratio 0·32 [95% CI 0·27-0·37]) and 82% at 8 weeks (0·18 [0·14-0·23]) following the week in which significant changes in population movements were recorded. INTERPRETATION: The introduction of COVID-19 containment policies and public information campaigns likely reduced transmission of S pneumoniae, H influenzae, and N meningitidis, leading to a significant reduction in life-threatening invasive diseases in many countries worldwide. FUNDING: Wellcome Trust (UK), Robert Koch Institute (Germany), Federal Ministry of Health (Germany), Pfizer, Merck, Health Protection Surveillance Centre (Ireland), SpID-Net project (Ireland), European Centre for Disease Prevention and Control (European Union), Horizon 2020 (European Commission), Ministry of Health (Poland), National Programme of Antibiotic Protection (Poland), Ministry of Science and Higher Education (Poland), Agencia de Salut Pública de Catalunya (Spain), Sant Joan de Deu Foundation (Spain), Knut and Alice Wallenberg Foundation (Sweden), Swedish Research Council (Sweden), Region Stockholm (Sweden), Federal Office of Public Health of Switzerland (Switzerland), and French Public Health Agency (France).


Assuntos
Infecções Bacterianas/epidemiologia , COVID-19 , Infecções Respiratórias/epidemiologia , Infecções Bacterianas/transmissão , COVID-19/prevenção & controle , Haemophilus influenzae , Humanos , Incidência , Análise de Séries Temporais Interrompida , Neisseria meningitidis , Vigilância da População , Estudos Prospectivos , Prática de Saúde Pública , Streptococcus agalactiae , Streptococcus pneumoniae
2.
Vaccine ; 29(10): 1959-67, 2011 Feb 24.
Artigo em Inglês | MEDLINE | ID: mdl-21215830

RESUMO

Pneumococcal conjugate vaccines (PCV) may reduce nasopharyngeal carriage (NPC) of Streptococcus pneumoniae vaccine strains (VT), but serotype replacement with non-vaccine strains (NVT) has been reported. Bacterial NPC after PHiD-CV vaccination was assessed in the second year of life. Open descriptive study of NPC reported for 414 subjects vaccinated at 3-5 and 12-15 months of age with PHiD-CV with or without prophylactic paracetamol (PP) compared to 336 age-matched PCV-naïve controls. Carriage was assessed prior to and 1, 3, 7 and 12 months after PHiD-CV booster or MenACWY-TT control vaccination at 12-15 months of age. At each visit, carriage of VT was reduced by 22-35% in PHiD-CV recipients. Vaccine efficacy across all visits was 21.7% [95% CI 2.6; 37.0] (26.8% carriage in the PHiD-CV group versus 34.2% in controls). Carriage rates of NVT tended to be higher in PHiD-CV recipients. Pre-booster, these findings were more pronounced when PP had not been administered. No substantial effect of PHiD-CV vaccination was observed on NPC of other bacterial pathogens including non-typeable Haemophilus influenzae. Primary and booster vaccination with PHiD-CV reduced NPC of VT in the second year of life and tended to slightly increase that of NVT in line with previous experience with the 7-valent PCV.


Assuntos
Portador Sadio/prevenção & controle , Infecções por Haemophilus/prevenção & controle , Haemophilus influenzae/isolamento & purificação , Nasofaringe/microbiologia , Infecções Pneumocócicas/prevenção & controle , Vacinas Pneumocócicas/imunologia , Streptococcus pneumoniae/isolamento & purificação , Feminino , Humanos , Imunização Secundária/métodos , Lactente , Masculino , Vacinas Pneumocócicas/administração & dosagem , Vacinação/métodos
4.
Klin Mikrobiol Infekc Lek ; 10(3): 118-23, 2004 Jun.
Artigo em Tcheco, Inglês | MEDLINE | ID: mdl-15227602

RESUMO

OBJECTIVES: The paper is an analysis of the results of a five-year surveillance programme in the Czech Republic (1999-2003); it evaluates the efficacy of routine Hib vaccination that started in July 2001. MATERIAL AND METHODS: Morbidity due to Hib was explored in a surveillance programme, which since 2002 also included the investigation of Hib vaccine failure. Hib identification was carried out with standard methods, serotypes were verified using PCR, biotyping was carried out in all strains and in selected strains also multilocus sequential typing. RESULTS: In the years 1999-2003 invasive Hib disease presented mostly as meningitis, followed by epiglottitis. Mortality due to an invasive Hib disease was in the years 1999-2003 2.3 %. Among the Hib strains isolated in invasive disorders predominated the biotype I and the sequence type ST-6. CONCLUSIONS: Following the introduction of routine Hib vaccination in the Czech Republic there was an overall drop in morbidity due to Hib invasive disorders. This was most obvious in a decrease in the morbidity of Hib meningitis and in the vaccinated age group. Two years after the introduction of routine Hib vaccination morbidity dropped by 81 % in children aged 0 to 1 year. In higher age groups there was no change in the number of invasive Hib disease. Neither was there an increase in "non-b" haemophilus invasive disorders. Failure of Hib vaccination is a rare occurence.


Assuntos
Infecções por Haemophilus , Haemophilus influenzae tipo b , República Tcheca , Humanos , Incidência , Lactente , Vacinação
5.
Klin Mikrobiol Infekc Lek ; 10(1): 22-4, 2004 Feb.
Artigo em Tcheco | MEDLINE | ID: mdl-15100979

RESUMO

Invasive Haemophilus influenzae b (Hib) diseases are rarely observed in children with vaccination against Hib. Immunisation of infants against Hib was introduced in the Czech Republic in 2001. The first case of meningitis with isolation of Hib in child immunised with Hib vaccine since starting routine vaccination is described. Clinical course of meningitis was mild and was identical with previously manifestation of Hib meningitis.


Assuntos
Vacinas Anti-Haemophilus/administração & dosagem , Meningite por Haemophilus/prevenção & controle , Polissacarídeos Bacterianos/administração & dosagem , Vacinação , Cápsulas Bacterianas , Humanos , Lactente , Masculino , Meningite por Haemophilus/diagnóstico , Meningite por Haemophilus/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA